MedImmune joins research collaboration with the University of California

MedImmune joins research collaboration with the University of California


MedImmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca,…

Antibiotics and Infectious diseasesCardio-vascularInflammatory diseasesMedImmuneMetabolicsNeurologicalOncologyPharmaceuticalResearchRespiratory and PulmonaryUSA

AstraZeneca's Brilinta gains Class I in ACCF/AHA Guidelines; enters deal with Progenics


Anglo-Swedish drug major AstraZeneca (LSE: AZN) announced yesterday that a combined panel of experts…

Antibiotics and Infectious diseasesAstraZenecaBrilintaCardio-vascularLicensingMedImmunePharmaceuticalProgenics PharmaceuticalsRegulation

PDL BioPharma to pay MedImmune $92.5 million to resolve patent disputes; Mylan debuts generic Vfend


PDL BioPharma (Nasdaq: PDLI) saw its shares drop 3.5% to $5.25 after the company said it had entered…

Antibiotics and Infectious diseasesAstraZenecaFinancialGenericsMedImmuneMylan LaboratoriesNorth AmericaPatentsPDL BioPharmaPfizerPharmaceuticalRespiratory and PulmonarySynagisVfend

AstraZeneca’s MedImmune unit in licensing deal with Phylogica for antimicrobial peptide


Australian drug discovery firm Phylogica (ASX: PYC, XETRA: PH7) has entered into an agreement with Anglo-Swedish…

Antibiotics and Infectious diseasesAstraZenecaLicensingMedImmunePharmaceuticalPhylogicaResearch

Back to top